Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?

Benzer Materyaller

• Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
  Yazar:: Mitja Krajnc, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-03-01)
• Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
  Yazar:: Hongzhong Liu, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-04-01)
• Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U‐100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring
  Yazar:: Yuji Kawaguchi, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-05-01)
• Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes
  Yazar:: Torre E, ve diğerleri
  Baskı/Yayın Bilgisi: (2018-07-01)
• Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
  Yazar:: Ran Wei, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)